Media headlines about Johnson & Johnson (NYSE:JNJ) have trended very negative this week, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Johnson & Johnson earned a media sentiment score of -3.00 on their scale. InfoTrie also assigned news stories about the company an news buzz score of 10 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company’s share price in the immediate future.
These are some of the media headlines that may have impacted Johnson & Johnson’s score:
- Dow Movers: WBA, JNJ (msn.com)
- Markets Right Now: Stocks fall for the 2nd day in a row (marketbeat.com)
- US stocks slide; market on track for second straight loss (marketbeat.com)
- Stocks veer lower, led by drops in tech companies and banks (marketbeat.com)
- Markets Right Now: US stocks are mixed in early trading (marketbeat.com)
Several equities analysts have recently issued reports on JNJ shares. Goldman Sachs Group started coverage on Johnson & Johnson in a report on Tuesday, May 28th. They issued a “buy” rating for the company. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 price objective for the company in a report on Wednesday, March 27th. Morgan Stanley boosted their price objective on Johnson & Johnson from $134.00 to $145.00 and gave the company an “equal weight” rating in a report on Wednesday, April 17th. Citigroup boosted their price objective on Johnson & Johnson from $139.00 to $147.00 and gave the company a “neutral” rating in a report on Monday, February 25th. Finally, Credit Suisse Group boosted their price objective on Johnson & Johnson from $152.00 to $156.00 and gave the company an “outperform” rating in a report on Thursday, May 16th. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $147.30.
Johnson & Johnson stock opened at $141.68 on Thursday. The company has a market capitalization of $371.12 billion, a PE ratio of 17.32, a price-to-earnings-growth ratio of 2.42 and a beta of 0.70. Johnson & Johnson has a 12 month low of $120.11 and a 12 month high of $148.99. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.44 and a quick ratio of 1.13.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 16th. The company reported $2.10 EPS for the quarter, beating the Zacks’ consensus estimate of $2.03 by $0.07. The business had revenue of $20.02 billion during the quarter, compared to analysts’ expectations of $19.55 billion. Johnson & Johnson had a return on equity of 36.29% and a net margin of 17.99%. The business’s revenue was up .1% compared to the same quarter last year. During the same period in the previous year, the business earned $2.06 earnings per share. As a group, equities analysts predict that Johnson & Johnson will post 8.6 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 11th. Stockholders of record on Tuesday, May 28th were given a $0.95 dividend. The ex-dividend date was Friday, May 24th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.90. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.68%. Johnson & Johnson’s payout ratio is 46.45%.
In other news, Director Marillyn A. Hewson purchased 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 11th. The stock was purchased at an average cost of $139.68 per share, for a total transaction of $419,040.00. Following the completion of the transaction, the director now owns 3,000 shares of the company’s stock, valued at $419,040. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.23% of the stock is owned by insiders.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: What are the Benefits of Index Funds?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.